Drug Profile
Research programme: neurological disorder therapeutics - Merck Serono/San Raffaele Institute
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck Serono
- Developer Merck Serono; Scientific Institute San Raffaele
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis; Neurodegenerative disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Italy
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Italy
- 13 Dec 2010 Preclinical trials in Multiple sclerosis in Italy (unspecified route)